Age-dependent neuroectodermal differentiation capacity of human mesenchymal stromal cells: limitations for autologous cell replacement strategies. 2010

Andreas Hermann, and Catrin List, and Hans-Jörg Habisch, and Vladimir Vukicevic, and Monika Ehrhart-Bornstein, and Rolf Brenner, and Peter Bernstein, and Stefan Fickert, and Alexander Storch
Department of Neurology, Dresden University of Technology, Dresden, Germany.

OBJECTIVE Human adult bone marrow (BM)-derived mesenchymal stromal cells (hMSC) are reported to break germ layer commitment and differentiate into cells expressing neuroectodermal properties. Although it is of pivotal interest for cell replacement therapies for neurologic disorders, no data exist on the influence of the donor's age on this multipotent differentiation behavior. METHODS We evaluated various epigenetic neuroectodermal conversion protocols in adult hMSC derived from older donors (>45 versus 18-35 years of age) using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and immunocytochemistry. The protocols included single- and multi-step conversion-differentiation protocols combined with co-culture techniques. Furthermore, the age dependency of mesodermal differentiation potential and cell senescence were investigated. RESULTS The neuroectodermal differentiation potential of hMSC derived from old donors was completely lost, with no cells showing mature neuroectodermal phenotypes using single- and multi-step conversion-differentiation protocols and no improvement of neurogenesis by various co-culture conditions. Comparison of young versus old donor-derived hMSC showed fewer cells expressing early neuroectodermal marker proteins in the latter samples. qRT-PCR showed reduced expression of the proliferation marker KI67 and the neuroectodermal gene NES (nestin) in old donor-derived cells compared with young donor hMSC. Telomere length analysis showed no general cell aging. CONCLUSIONS Our data provide evidence that only young donor-derived hMSC can be epigenetically differentiated in vitro into neuroectodermal cells, pointing towards senescence of multipotentiality of old donor-derived hMSC. There is thus an urgent need to develop better protocols for successful neuroectodermal differentiation of hMSC from old individuals as a prerequisite for autologous cell replacement strategies for neurologic diseases in elderly patients.

UI MeSH Term Description Entries
D007381 Intermediate Filament Proteins Filaments 7-11 nm in diameter found in the cytoplasm of all cells. Many specific proteins belong to this group, e.g., desmin, vimentin, prekeratin, decamin, skeletin, neurofilin, neurofilament protein, and glial fibrillary acid protein. Fibroblast Intermediate Filament Proteins,Filament Proteins, Intermediate,Proteins, Intermediate Filament
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D009420 Nervous System The entire nerve apparatus, composed of a central part, the brain and spinal cord, and a peripheral part, the cranial and spinal nerves, autonomic ganglia, and plexuses. (Stedman, 26th ed) Nervous Systems,System, Nervous,Systems, Nervous
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000075202 Contraindications A condition or factor associated with a recipient that makes the use of a drug, procedure, or physical agent improper or inadvisable. Contraindications may be absolute (life threatening) or relative (higher risk of complications in which benefits may outweigh risks). Contraindications, Physical Agent,Medical Contraindications,Agent Contraindication, Physical,Agent Contraindications, Physical,Contraindication,Contraindication, Medical,Contraindication, Physical Agent,Contraindications, Medical,Medical Contraindication,Physical Agent Contraindication,Physical Agent Contraindications
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Andreas Hermann, and Catrin List, and Hans-Jörg Habisch, and Vladimir Vukicevic, and Monika Ehrhart-Bornstein, and Rolf Brenner, and Peter Bernstein, and Stefan Fickert, and Alexander Storch
January 2022, Frontiers in molecular neuroscience,
Andreas Hermann, and Catrin List, and Hans-Jörg Habisch, and Vladimir Vukicevic, and Monika Ehrhart-Bornstein, and Rolf Brenner, and Peter Bernstein, and Stefan Fickert, and Alexander Storch
June 2006, Journal of neuroscience research,
Andreas Hermann, and Catrin List, and Hans-Jörg Habisch, and Vladimir Vukicevic, and Monika Ehrhart-Bornstein, and Rolf Brenner, and Peter Bernstein, and Stefan Fickert, and Alexander Storch
August 2018, Injury,
Andreas Hermann, and Catrin List, and Hans-Jörg Habisch, and Vladimir Vukicevic, and Monika Ehrhart-Bornstein, and Rolf Brenner, and Peter Bernstein, and Stefan Fickert, and Alexander Storch
January 2011, Methods in molecular biology (Clifton, N.J.),
Andreas Hermann, and Catrin List, and Hans-Jörg Habisch, and Vladimir Vukicevic, and Monika Ehrhart-Bornstein, and Rolf Brenner, and Peter Bernstein, and Stefan Fickert, and Alexander Storch
July 2009, Journal of tissue engineering and regenerative medicine,
Andreas Hermann, and Catrin List, and Hans-Jörg Habisch, and Vladimir Vukicevic, and Monika Ehrhart-Bornstein, and Rolf Brenner, and Peter Bernstein, and Stefan Fickert, and Alexander Storch
June 2017, Stem cells (Dayton, Ohio),
Andreas Hermann, and Catrin List, and Hans-Jörg Habisch, and Vladimir Vukicevic, and Monika Ehrhart-Bornstein, and Rolf Brenner, and Peter Bernstein, and Stefan Fickert, and Alexander Storch
April 2014, Tissue engineering. Part A,
Andreas Hermann, and Catrin List, and Hans-Jörg Habisch, and Vladimir Vukicevic, and Monika Ehrhart-Bornstein, and Rolf Brenner, and Peter Bernstein, and Stefan Fickert, and Alexander Storch
June 2014, Tissue engineering. Part A,
Andreas Hermann, and Catrin List, and Hans-Jörg Habisch, and Vladimir Vukicevic, and Monika Ehrhart-Bornstein, and Rolf Brenner, and Peter Bernstein, and Stefan Fickert, and Alexander Storch
February 2020, Cells,
Andreas Hermann, and Catrin List, and Hans-Jörg Habisch, and Vladimir Vukicevic, and Monika Ehrhart-Bornstein, and Rolf Brenner, and Peter Bernstein, and Stefan Fickert, and Alexander Storch
February 2020, International journal of biological macromolecules,
Copied contents to your clipboard!